Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

High sensitive C-reactive protein and serum amyloid A are inversely related to serum bilirubin: effect-modification by metabolic syndrome

Authors: Petronella E Deetman, Stephan JL Bakker, Robin PF Dullaart

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Bilirubin has been implicated in cardiovascular protection by virtue of its anti-inflammatory and anti-oxidative properties. The metabolic syndrome is featured by enhanced low-grade systemic inflammation and oxidative stress. Serum amyloid A (SAA) impairs anti-oxidative properties of high-density lipoprotein (HDL). We determined relationships of high sensitive C-reactive protein (hs-CRP) and SAA with bilirubin in subjects with and without metabolic syndrome (MetS).

Methods

Serum total bilirubin, hs-CRP, SAA and homeostasis model assessment- insulin resistance (HOMA-IR) were documented in 94 subjects with and in 73 subjects without MetS (26 and 54 subjects with type 2 diabetes mellitus (T2DM), respectively).

Results

Bilirubin was lower in MetS (P = 0.013), coinciding with higher hs-CRP (P < 0.001) and SAA levels (P = 0.002). In all subjects combined, hs-CRP was inversely related to bilirubin (r = −0.203, P = 0.008), irrespective of the presence of MetS or T2DM (interaction terms: P ≥ 0.75). The inverse relationship of bilirubin with SAA was confined to subjects without MetS (r = −0.267, P = 0.009). Furthermore, the presence of either MetS or T2DM modified the relationship of bilirubin with SAA (interaction terms: β = 0.366, P = 0.003 and β = 0.289, P = 0.025, respectively) in age- and sex-adjusted analyses. Effect modification was also found for HOMA-IR (β = 0.790, P = 0.020). Of the individual MetS components, the strongest interaction of bilirubin on SAA was observed with low HDL cholesterol (β = 0.435, P < 0.001).

Conclusions

hs-CRP is inversely related to bilirubin, suggesting that low bilirubin is implicated in enhanced low-grade systemic inflammation. The inverse relationship of SAA with bilirubin was found to be absent in MetS, which could be attributable to MetS-associated abnormalities in HDL characteristics.
Appendix
Available only for authorised users
Literature
1.
Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, Tedesco F, Tiribelli C: Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun. 2009, 386 (2): 338-344. 10.1016/j.bbrc.2009.06.029.CrossRefPubMed
2.
Abraham NG, Kappas A: Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med. 2005, 39 (1): 1-25. 10.1016/j.freeradbiomed.2005.03.010.CrossRefPubMed
3.
4.
Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004, 89 (10): 4963-4971. 10.1210/jc.2004-0305.CrossRefPubMed
5.
Choi SH, Yun KE, Choi HJ: Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis. 2013, 23 (1): 31-37. 10.1016/j.numecd.2011.03.001.CrossRefPubMed
6.
Robertson RP, Harmon JS: Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med. 2006, 41 (2): 177-184. 10.1016/j.freeradbiomed.2005.04.030.CrossRefPubMed
7.
Kim KM, Kim BT, Park SB, Cho DY, Je SH, Kim KN: Serum total bilirubin concentration is inversely correlated with Framingham risk score in Koreans. Arch Med Res. 2012, 43 (4): 288-293. 10.1016/j.arcmed.2012.05.003.CrossRefPubMed
8.
Kang SJ, Kim D, Park HE, Chung GE, Choi SH, Choi SY, Lee W, Kim JS, Cho SH: Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis. Atherosclerosis. 2013, 230 (2): 242-248. 10.1016/j.atherosclerosis.2013.06.021.CrossRefPubMed
9.
Vitek L, Novotny L, Sperl M, Holaj R, Spacil J: The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis. 2006, 21 (5–6): 408-414.PubMed
10.
Yoshino S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Oketani N, Saihara K, Okui H, Shinsato T, Ichiki H, Kubozono T, Kuwahata S, Fujita S, Kanda D, Nakazaki M, Miyata M, Tei C: Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J Atheroscler Thromb. 2011, 18 (5): 403-412. 10.5551/jat.6346.CrossRefPubMed
11.
Dullaart RP, Kappelle PJ, De Vries R: Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects. Clin Chim Acta. 2012, 414: 161-165.CrossRefPubMed
12.
Novotny L, Vitek L: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003, 228 (5): 568-571.
13.
Chan KH, O’Connell RL, Sullivan DR, Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC: FIELD study investigators: plasma total Bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2013, 56 (4): 724-736. 10.1007/s00125-012-2818-4.CrossRefPubMed
14.
Ajja R, Lee DC, Sui X, Church TS, Steven NB: Usefulness of serum Bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol. 2011, 108 (10): 1438-1442. 10.1016/j.amjcard.2011.06.067.PubMedCentralCrossRefPubMed
15.
Vitek L, Schwertner HA: The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007, 43: 1-57.CrossRefPubMed
16.
Hwang HJ, Lee SW, Kim SH: Relationship between Bilirubin and C-reactive protein. Clin Chem Lab Med. 2011, 49 (11): 1823-1828.CrossRefPubMed
17.
Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC, Wagner KH: Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert’s syndrome. Clin Sci (Lond). 2013, 125 (5): 257-264. 10.1042/CS20120661.CrossRef
18.
Dullaart RP, De Boer JF, Annema W, Tietge UJ: The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity (Silver Spring). 2013, 21 (2): 361-366. 10.1002/oby.20058.CrossRef
19.
Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006, 58 (3): 342-374. 10.1124/pr.58.3.1.CrossRefPubMed
20.
Nofer J: Serum amyloid A concentration may reflect HDL functionality. Clin Lipidol. in press
21.
Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000, 342 (12): 836-843. 10.1056/NEJM200003233421202.CrossRefPubMed
22.
Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000, 321 (7255): 199-204. 10.1136/bmj.321.7255.199.PubMedCentralCrossRefPubMed
23.
Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE: National Heart, Lung, and Blood Institute: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004, 109 (6): 726-732. 10.1161/01.CIR.0000115516.54550.B1.CrossRefPubMed
24.
Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP: Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res. 2011, 42 (3): 219-225. 10.1016/j.arcmed.2011.05.002.CrossRefPubMed
25.
Jylhava J, Haarala A, Eklund C, Pertovaara M, Kahonen M, Hutri-Kahonen N, Levula M, Lehtimaki T, Huupponen R, Jula A, Juonala M, Viikari J, Raitakari O, Hurme M: Serum amyloid a is independently associated with metabolic risk factors but not with early atherosclerosis: the cardiovascular risk in young Finns study. J Intern Med. 2009, 266 (3): 286-295. 10.1111/j.1365-2796.2009.02120.x.CrossRefPubMed
26.
Den Engelsen C, Koekkoek PS, Gorter KJ, Van den Donk M, Salome PL, Rutten GE: High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol. 2012, 11: 25-2840. 10.1186/1475-2840-11-25. 11-25PubMedCentralCrossRefPubMed
27.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: American Heart Association, National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112 (17): 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed
28.
Tisdale WA, Klatskin G, Kinsella ED: The significance of the direct-reacting fraction of serum Bilirubin in hemolytic jaundice. Am J Med. 1959, 26 (2): 214-227. 10.1016/0002-9343(59)90310-9.CrossRefPubMed
29.
Zelle DM, Deetman N, Alkhalaf A, Navis G, Bakker SJ: Support for a protective effect of Bilirubin on diabetic nephropathy in humans. Kidney Int. 2011, 79 (6): 686-7.CrossRefPubMed
30.
Katsiki N, Karagiannis A, Mikhailidis DP: Diabetes, bilirubin and amputations: is there a link?. Diabetologia. 2013, 56 (4): 683-685. 10.1007/s00125-013-2840-1.CrossRefPubMed
31.
Deetman PE, Zelle DM, Van der Heide JJ H, Navis GJ, Gans RO, Bakker SJ: Plasma bilirubin and late graft failure in renal transplant recipients. Transpl Int. 2012, 25 (8): 876-881. 10.1111/j.1432-2277.2012.01515.x.CrossRefPubMed
32.
Hazenberg BP, Limburg PC, Bijzet J, Van Rijswijk MH: A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis. 1999, 58 (2): 96-102. 10.1136/ard.58.2.96.PubMedCentralCrossRefPubMed
33.
Selvin S: Statistical Analysis of Epidemiological Data. 1996, New York: Oxford University Press
34.
Lu M, Lyden PD, Brott TG, Hamilton S, Broderick JP, Grotta JC: Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods. 2005, 143 (2): 209-216. 10.1016/j.jneumeth.2004.10.002.CrossRefPubMed
35.
Jenko-Praznikar Z, Petelin A, Jurdana M, Ziberna L: Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: An early indicator of metabolic syndrome?. Metabolism. 2013, 62 (7): 976-985. 10.1016/j.metabol.2013.01.011.CrossRefPubMed
36.
Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, Lin JL: Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis. 2009, 203 (2): 563-568. 10.1016/j.atherosclerosis.2008.07.021.CrossRefPubMed
37.
Ohnaka K, Kono S, Inoguchi T, Yin G, Morita M, Adachi M, Kawate H, Takayanagi R: Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract. 2010, 88 (1): 103-110. 10.1016/j.diabres.2009.12.022.CrossRefPubMed
38.
Basiglio CL, Arriaga SM, Pelusa F, Almara AM, Kapitulnik J, Mottino AD: Complement activation and disease: protective effects of hyperbilirubinaemia. Clin Sci (Lond). 2009, 118 (2): 99-113. 10.1042/CS20080540.CrossRef
39.
Rocuts F, Zhang X, Yan J, Yue Y, Thomas M, Bach FH, Czismadia E, Wang H: Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant. 2010, 19 (4): 443-451. 10.3727/096368909X484680.CrossRefPubMed
40.
Rutter MK, Meigs JB, Sullivan LM, D’Agostino RBS, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004, 110 (4): 380-385. 10.1161/01.CIR.0000136581.59584.0E.CrossRefPubMed
41.
Garin MC, Kalix B, Morabia A, James RW: Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2005, 90 (4): 2264-2269. 10.1210/jc.2004-1295.CrossRefPubMed
42.
Dullaart RP, Kwakernaak AJ, Dallinga-Thie GM: The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis. 2013, 230 (1): 6-11. 10.1016/j.atherosclerosis.2013.06.019.CrossRefPubMed
Metadata
Title
High sensitive C-reactive protein and serum amyloid A are inversely related to serum bilirubin: effect-modification by metabolic syndrome
Authors
Petronella E Deetman
Stephan JL Bakker
Robin PF Dullaart
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-166

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Original investigation

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus

Original investigation

Urinary adiponectin concentration is positively associated with micro- and macro-vascular complications

Original investigation

Cardiovascular risk escalation with caloric excess: a prospective demonstration of the mechanics in healthy adults

Original investigation

Do patients with type 1 and type 2 diabetes really have an impaired endothelial function? A population-based propensity score matching analysis

Original investigation

Protein kinase RNA- like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)- mediated endoplasmic reticulum stress- induced apoptosis in diabetic cardiomyopathy

Original investigation

Plasma copeptin levels are inversely associated with intima-media-thickness in men: the population-based KORA F4 study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits